Wingtech

Wingtech Pharmaceutical is a clinical-stage biotechnology company based in Wuxi, China, specializing in the discovery and development of innovative small molecule therapeutics for metabolic and inflammatory diseases. The company's research focuses on high-impact indications such as non-alcoholic steatohepatitis (NASH), obesity, type 2 diabetes, and gout. Wingtech's pipeline includes several advanced candidates, notably multi-target agonists and selective inhibitors designed for oral administration. By leveraging its proprietary small molecule discovery platform, the company aims to optimize drug properties for improved efficacy and patient compliance. Wingtech has attracted significant investment from prominent venture capital firms to accelerate its clinical programs toward commercialization.